<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Pathology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7B37377E-AAF0-4C32-BA3D-0395632DCBB7"><gtr:id>7B37377E-AAF0-4C32-BA3D-0395632DCBB7</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:otherNames>Leether</gtr:otherNames><gtr:surname>Griffin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C53E9AC8-797D-4EC7-AFDA-E26B44522257"><gtr:id>C53E9AC8-797D-4EC7-AFDA-E26B44522257</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:surname>Cooke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801841"><gtr:id>C0906DE5-69FA-4CF8-927E-E3BB5DC40E2C</gtr:id><gtr:title>Using an animal model of type 1 diabetes to identify biomarkers of pre-symptomatic disease and treatment efficacy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801841</gtr:grantReference><gtr:abstractText>In type 1 diabetes the immune system of an individual selectively destroys the cells in the body that secrete insulin, a hormone which is essential for maintaining glucose levels in the body. This autoimmune process can be going on for several years before sufficient insulin producing cells have been killed to make the person clinically ill. If you could detect those people who were suffering from such an autoimmune condition before they became clinically ill it would be possible to intervene therapeutically to prevent further loss of these very important cells. Such an early intervention would mean that there would be no need to have daily insulin injections and would prevent the development of diabetic complications. Therefore if biomarkers could be detected in blood samples this would represent a significant advance towards a better treatment for type 1 diabetes.</gtr:abstractText><gtr:technicalSummary>Type 1 diabetes arises as a result of autoimmune destruction of the pancreatic beta cells. It is known that the autoreactive destruction of the beta cells may have been occurring for years before diabetes onset. It would be advantageous to be able to fully identify susceptible individuals and intervene with a tolerogenic protocol before irrevocable beta cell destruction occurs. We propose to use the established NOD mouse model of type 1 diabetes, and specific interventions currently being examined in the Cooke laboratory, to identify biomarkers of underlying pathological processes at the pre-symptomatic stage of the disease. We will determine whether the biomarkers we identify provide a) accurate markers of predisposition to develop diabetes and b) can be used to monitor the success of therapeutic intervention. This would represent a considerable advance in the potential treatment of type 1 diabetes.</gtr:technicalSummary><gtr:fund><gtr:end>2012-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>463103</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Biological Sciences Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biochemistry</gtr:department><gtr:description>Biomarkers and Type 1 diabetes</gtr:description><gtr:id>86247524-B7FB-4A5B-9E19-D52B5F2413EC</gtr:id><gtr:impact>None so far apart from meeting abstracts.</gtr:impact><gtr:partnerContribution>Dr Griffin and I have an MRC project grant to study biomarkers associated with Type 1 diabetes</gtr:partnerContribution><gtr:piContribution>We supply the material from diabetes protected NOD mice for biomarker analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rheumatology Department</gtr:department><gtr:description>Mevalonate pathway in inflammation with Kings College London Department of Rheumatology</gtr:description><gtr:id>7A12A75C-B243-4767-875F-8780DB0160F6</gtr:id><gtr:impact>Biomarker discovery for arthritic disease</gtr:impact><gtr:partnerContribution>This is currently being set up but will involve supply ofpatient material</gtr:partnerContribution><gtr:piContribution>This is currently being set up but will involve metabolomics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>2nd Metabolomics Sardinian Scientific School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>18650FC5-1A6C-4F08-8D5A-2FD8E89BFD68</gtr:id><gtr:impact>2nd Metabolomics Sardinian Scientific School was aimed at post-grad students new to the field of metabolomics. We gave seminars and workshops in various tools and techniques in metabolomics.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D80016EF-3114-4165-B02D-62DA505D072C"><gtr:id>D80016EF-3114-4165-B02D-62DA505D072C</gtr:id><gtr:title>The study of mammalian metabolism through NMR-based metabolomics.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d92cf36c0bdb3d82360a12275653cef"><gtr:id>3d92cf36c0bdb3d82360a12275653cef</gtr:id><gtr:otherNames>Salek R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E185E7BF-22D2-4495-A8BD-C3EC01563A8C"><gtr:id>E185E7BF-22D2-4495-A8BD-C3EC01563A8C</gtr:id><gtr:title>Metabolomics as a tool for cardiac research.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0fa52afc678c4e6d52598c663a0af7a"><gtr:id>d0fa52afc678c4e6d52598c663a0af7a</gtr:id><gtr:otherNames>Griffin JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-5002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA9D6B38-6A4A-46AA-AC49-5245AB792B1D"><gtr:id>CA9D6B38-6A4A-46AA-AC49-5245AB792B1D</gtr:id><gtr:title>The nonconventional MHC class II molecule DM governs diabetes susceptibility in NOD mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78a482a0cf30e47790cf90a173aa5869"><gtr:id>78a482a0cf30e47790cf90a173aa5869</gtr:id><gtr:otherNames>Morgan MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/19EDD75C-927C-4F50-BCDB-706A4DBF3493"><gtr:id>19EDD75C-927C-4F50-BCDB-706A4DBF3493</gtr:id><gtr:title>Accelerated turnover of MHC class II molecules in nonobese diabetic mice is developmentally and environmentally regulated in vivo and dispensable for autoimmunity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e50222550ee35548e6fb217fb6564d49"><gtr:id>e50222550ee35548e6fb217fb6564d49</gtr:id><gtr:otherNames>De Riva A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E300A12E-A485-4488-83E7-6DA33C53B917"><gtr:id>E300A12E-A485-4488-83E7-6DA33C53B917</gtr:id><gtr:title>Mechanistic insights revealed by lipid profiling in monogenic insulin resistance syndromes.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dbf95ec29a8570e7cba45b6531f6cb39"><gtr:id>dbf95ec29a8570e7cba45b6531f6cb39</gtr:id><gtr:otherNames>Eiden M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801841</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>